Julia Draznin
Overview
Explore the profile of Julia Draznin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lian L, Wang Y, Draznin J, Eslin D, Bennett J, Poncz M, et al.
Blood
. 2005 Feb;
106(1):110-7.
PMID: 15705797
Stimulation of platelet G protein-coupled receptors results in the cleavage of phosphatidylinositol 4,5-trisphosphate (PIP(2)) into inositol 1,4,5-trisphosphate and 1,2-diacylglycerol by phospholipase C (PLCbeta). It also results in the phosphorylation of...
2.
Draznin J
Acad Med
. 2004 Mar;
79(4):289-90.
PMID: 15044159
For years women have been fighting for equity in the academic work place, but this acceptance comes at a price. Balancing work and family obligations have proven to be an...
3.
Sollecito T, Draznin J, Parisi E, Duffy K, Stadtmauer E, Luger S, et al.
Spec Care Dentist
. 2003 Dec;
23(3):108-10.
PMID: 14650559
Treatment options are limited for patients with relapsed acute myelogenous leukemia (AML), particularly when the disease is refractory to standard cytotoxic chemotherapy. Targeted drug therapy offers the advantage of delivering...
4.
Parisi E, Draznin J, Stoopler E, Schuster S, Porter D, Sollecito T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
. 2002 Apr;
93(3):257-63.
PMID: 11925533
Acute myelogenous leukemia (AML) describes a group of related hematologic malignancies that are being approached therapeutically from several perspectives. Conventional chemotherapeutic agents, such as anthracyclines and cytosine arabinoside (Ara-C), are...